Next Article in Journal
Screening of Filamentous Fungi to Identify Biocatalysts for Lupeol Biotransformation
Next Article in Special Issue
The Structural Diversity of Deoxyribozymes
Previous Article in Journal
Heterocyclic Analogues of Xanthone and Xanthione. 1H-Pyrano[2,3-c:6,5-c]dipyrazol-4(7H)-ones and Thiones: Synthesis and NMR Data
Previous Article in Special Issue
Generation and Development of RNA Ligase Ribozymes with Modular Architecture Through “Design and Selection”
Article Menu

Export Article

Open AccessReview
Molecules 2010, 15(9), 6127-6139;

A Therapeutic Approach to Nasopharyngeal Carcinomas by DNAzymes Targeting EBV LMP-1 Gene

Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, China
Center for Molecular Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410078, China
Department of Medical and Molecular Biosciences, University of Technology Sydney, Australia
Authors to whom correspondence should be addressed.
Received: 18 June 2010 / Revised: 26 August 2010 / Accepted: 30 August 2010 / Published: 1 September 2010
(This article belongs to the Special Issue Catalytic Nucleic Acids)
Full-Text   |   PDF [537 KB, uploaded 18 June 2014]   |  


Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) has been known to have oncogenic properties during latent infection in nasopharyngeal carcinoma (NPC). Genetic manipulation of LMP1 expression may provide a novel strategy for the treatment of NPC. DNAzymes are synthetic, single-stranded DNA catalysts that can be engineered to bind and cleave the target mRNA of a disease-causing gene. By targeting the LMP1 mRNA, we successfully obtained a phosphorothioate-modified ‘‘10–23’’ DNAzyme namely DZ1, through screening a series of DNAzymes. DZ1 could significantly down-regulate the expression of LMP1 in NPC cells, inhibit cell proliferation, metastasis, promote apoptosis and enhance radiosensitivity of NPC through interfering signal pathways which are abnormally activated by LMP1, including NF-κB, AP-1 and STAT3 signal pathways. Together, interfering LMP1 signaling pathway could be a promising strategy to target the malignant phenotypes of NPC. View Full-Text
Keywords: LMP1; DNAzyme; NPC; targeted therapy LMP1; DNAzyme; NPC; targeted therapy

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Yang, L.; Lu, Z.; Ma, X.; Cao, Y.; Sun, L.-Q. A Therapeutic Approach to Nasopharyngeal Carcinomas by DNAzymes Targeting EBV LMP-1 Gene. Molecules 2010, 15, 6127-6139.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top